We report that TAT-GILZ modulates inflammation and promotes efferocytosis and bacterial clearance resulting in decreased lung damage and barrier breech during pneumonia, while enhancing macrophages phagocytosis of bacteria, suggesting that the exploitation of GILZ-based therapeutics holds promise in the treatment of severe pneumonia. Here, TSC22D3 is linked to susceptibility to pneumonia measurement.